The Part D Subsidy Is Ending: What It Actually Means for Your 2027 Premium

By Paul Barrett, CMIP — Founder, The Modern Medicare Agency Licensed in 37 states · 18+ years Medicare-exclusive · Last updated July 30, 2026

Key Takeaways

• On July 28, 2026, CMS announced it will end the Part D Premium Stabilization Demonstration after the 2026 plan year, returning standalone Part D plans to “traditional market conditions” starting in 2027.
• This affects roughly 25 million Americans enrolled in standalone Part D prescription drug plans — it does not directly affect people whose drug coverage is bundled into a Medicare Advantage plan.
• CMS Administrator Dr. Mehmet Oz says most people will see premiums rise by less than $10 a month, with some seeing no increase or even a decrease. Consumer advocacy groups have pushed back, arguing even small increases are a real burden for people on fixed incomes.
• One important correction worth knowing: the Inflation Reduction Act’s 6% cap protects only a national average benchmark figure, not what your specific plan can charge — individual plan premiums are not capped and can rise by far more than 6% in a single year.
• Final 2027 premiums won’t be published until mid-to-late September 2026 — nothing changes for the rest of this year, and there’s no reason to make any decision before real numbers are available.
• No sales pitch here — just the facts, from multiple perspectives, so you can make sense of the calls and headlines without the spin.

What Actually Happened

On July 28, 2026, the Centers for Medicare & Medicaid Services (CMS) announced it will end the Part D Premium Stabilization Demonstration after the 2026 plan year. Starting in 2027, standalone Part D prescription drug plans return to what CMS is calling “traditional market conditions” — meaning insurers set their own premiums without the extra federal support this program provided.

Here’s the background. The demonstration was created by the Biden administration and launched for the 2025 plan year, following major changes to Part D required under the Inflation Reduction Act — most notably the new annual out-of-pocket cap on prescription drugs, which dropped to $2,100 for 2026. As insurers adjusted to that redesigned benefit structure, the government worried premiums could spike sharply and unpredictably in the transition. The stabilization program was built to smooth that transition: for 2025, it included a $15 uniform cut to the base beneficiary premium, capped year-over-year premium increases at $35, and narrowed the “risk corridors” that limit how much insurers gain or lose based on actual costs.

CMS now says insurers have “sufficient experience under the redesigned Part D benefit” to price their own plans accurately without that support — and is ending the program accordingly.

What This Means for Your Premium

The honest answer is: nobody knows your exact 2027 premium yet. CMS has said it won’t publish final, plan-specific 2027 premiums until mid-to-late September 2026.

What we do know so far:

• CMS Administrator Dr. Mehmet Oz stated publicly that premiums will increase by less than $10 a month for most Medicare recipients, with some beneficiaries seeing lower premiums. In a social media post announcing the change, Oz framed the prior program as unnecessary federal spending, writing that the prior administration “gave BILLIONS of taxpayer money DIRECTLY to Big Insurance Companies” and calling the shift a matter of “protecting the integrity of Medicare.”
• Consumer advocacy groups have pushed back. Protect Our Care, a nonprofit focused on healthcare affordability, argued that even a modest premium increase can be a real burden for seniors on fixed incomes, with one spokesperson noting that “even an extra $10 or $20 a month can mean choosing between filling their prescription, paying the electric bill, or buying groceries.”
• For 2027, CMS has set the national average monthly bid amount at $296.05 and the base beneficiary premium at $41.33 — figures used in calculating federal subsidy payments to insurers, though these are not the same as what any individual plan will actually charge.

Reasonable people can and do disagree about whether ending this program was the right call — that’s a political and policy question, not a factual one, and it’s not this article’s job to take a side on it. What matters practically is understanding the real range of outcomes, rather than assuming the worst (or the best) from a headline alone.

The Protection That’s Staying in Place — And What It Actually Covers

Here’s something that’s gotten less attention in the news coverage, and it’s important to get exactly right: the Inflation Reduction Act’s 6% cap applies only to the “national base beneficiary premium” — a national average benchmark figure used in federal calculations — not to what your specific plan actually charges you. That cap remains in effect through 2029, and it’s completely independent of the stabilization demonstration that’s ending. But it is not a shield around your individual monthly bill.

Think of the national base beneficiary premium as a government-calculated starting point, not a retail price. Private insurers use it as one input, then price their actual plans based on their own projected costs and risk — and there’s no limit on how much that final number can move. In 2025, for example, the most popular standalone Part D plan nationally, Wellcare Value Script, had a $0 premium in most states — but its California premium jumped from $0.40 to $17.40 in a single year, an increase with no meaningful ceiling on it at all. That’s the same year the national base beneficiary premium itself only rose 6%.

So yes, a real, legally binding 6% cap exists — it’s just capping a number that isn’t the number on your bill.

Who This Actually Affects

This change is specific to standalone Part D prescription drug plans — the kind people typically pair with Original Medicare or a Medigap policy. Roughly 25 million Americans are enrolled in a standalone Part D plan.

If your drug coverage is bundled into a Medicare Advantage plan (an MAPD plan), this specific announcement affects you less directly. Medicare Advantage plans negotiate their own drug coverage terms as part of their broader plan structure, and are not the focus of this particular program’s expiration. That’s not a guarantee your Medicare Advantage plan’s drug costs won’t change for 2027 — plans adjust every year for lots of reasons — but this specific subsidy program was built around the standalone Part D market.

The largest carriers in the standalone Part D market include UnitedHealth Group, Humana, and CVS Health’s Aetna.

What You Should Actually Do Right Now

Nothing, yet — and that’s genuinely good advice, not a brush-off.

1. Nothing changes for the rest of 2026. This affects 2027 plan pricing only.
2. Real, plan-specific numbers won’t exist until CMS publishes them in September. Any premium figure you see before then is an estimate or a national average, not what your specific plan will actually charge.
3. When those numbers come out, that’s the right time for a real annual review — comparing your actual drugs, your actual plan, and your actual alternatives. This is a normal part of reviewing Medicare coverage every year, subsidy program or not, and it lines up naturally with the run-up to the Annual Enrollment Period (October 15 – December 7).
4. If you’re on a Medicare Advantage plan with drug coverage included, this specific change matters less for you — though your annual plan review still matters just as much for other reasons.

Paul’s Honest Take

I’ve already gotten a handful of calls about this, and I understand why — “the government is ending a subsidy” sounds alarming out of context, especially before anyone has real numbers to look at. Here’s what I keep telling people: the honest range of outcomes here is genuinely uncertain right now, somewhere between “barely notice it” and “a real increase that matters,” depending on your specific plan and situation. Anyone telling you with total confidence exactly what’s going to happen to your premium in 2027 is guessing, because CMS itself hasn’t published that yet.

What I won’t do is tell you this is either nothing to worry about or a crisis — both of those would be dishonest before the actual numbers exist. What I will do is review your specific plan with you the moment real 2027 pricing is available, the same way I do every single year regardless of what’s in the news. That’s always been the job, and it still is.

Frequently Asked Questions

1. What is the Part D Premium Stabilization Demonstration? A temporary federal program, created by the Biden administration and launched for the 2025 plan year, designed to limit sudden or sharp premium increases for standalone Part D prescription drug plans as insurers adjusted to changes required under the Inflation Reduction Act.
2. When does the Part D subsidy program end? CMS announced on July 28, 2026 that the program will end after the 2026 plan year. Standalone Part D plans return to “traditional market conditions” starting with the 2027 plan year.
3. How much will my Part D premium go up in 2027? It’s not yet known for certain. CMS Administrator Dr. Mehmet Oz stated publicly that most beneficiaries should expect an increase of less than $10 a month, with some seeing lower premiums, but CMS will not publish final, plan-specific premiums until mid-to-late September 2026.
4. Does this affect my Medicare Advantage plan’s drug coverage? Not directly. This program specifically applies to standalone Part D prescription drug plans, typically paired with Original Medicare or a Medigap policy. Medicare Advantage plans with built-in drug coverage are not the direct focus of this program’s expiration, though your specific plan’s costs can still change year to year for other reasons.
5. Is there still a limit on how much my premium can increase? Not exactly, and this is an important nuance. The 6% cap applies only to the national base beneficiary premium — a national average benchmark used in federal calculations — not to what any individual plan actually charges. Individual plan premiums are not capped and can increase by far more than 6% in a single year.
6. How many people are affected by this change? Roughly 25 million Americans are enrolled in standalone Part D prescription drug plans nationwide.
7. Should I switch plans right now because of this news? No. Nothing changes until 2027, and final premium numbers for 2027 plans won’t be available until September 2026. Any decision made before that point would be based on estimates, not your actual options.
8. Why is the program ending? CMS stated that insurers now have “sufficient experience under the redesigned Part D benefit” to price their plans accurately without additional federal support, and characterized the program’s continuation as no longer necessary.
9. Are there different opinions on whether ending this program is a good idea? Yes. The administration frames the change as ending unnecessary spending and says most beneficiaries will see minimal impact. Consumer advocacy groups, including Protect Our Care, have argued that even modest premium increases represent a real burden for beneficiaries on fixed incomes. Both perspectives reflect genuine, reasonable disagreement about the trade-offs involved.
10. When will I know my actual 2027 Part D premium? CMS has stated it expects to release final, plan-specific 2027 premium information in mid-to-late September 2026, ahead of the Annual Enrollment Period that begins October 15.